Abrilumab在中重度溃疡性结肠炎随机安慰剂对照试验中的疗效与安全性
这项随机、2b期、安慰剂对照、双盲研究评估抗α4β7抗体Abrilumab治疗中重度溃疡性结肠炎的疗效与安全性。354例患者随机接受皮下Abrilumab(7、21、70或210 mg)或安慰剂,第8周时70 mg和210 mg组的缓解率显著高于安慰剂。Abrilumab诱导了缓解、临床应答和黏膜愈合,未发生进行性多灶性白质脑病或死亡。
要点
- 第8周缓解率:安慰剂4.3%,Abrilumab 70 mg组13.3%,210 mg组12.7%,两剂量组均显著高于安慰剂。
- Abrilumab 70 mg和210 mg组的临床应答和黏膜愈合率也显著高于安慰剂。
- 基线初始CD4+ T细胞α4β7水平较高是总体结局的预后指标,但不是Abrilumab应答的预测生物标志物。
核心结论
- Abrilumab治疗8周在中重度溃疡性结肠炎患者中诱导了缓解、临床应答和黏膜愈合。
研究设计与样本
- 随机、2b期、安慰剂对照、双盲研究,纳入总Mayo评分6-12分且直肠乙状结肠镜评分≥2分、对常规治疗应答不足或不耐受的患者。
- 354例患者接受至少1剂研究药物:安慰剂n=116,Abrilumab 7 mg n=21,21 mg n=40,70 mg n=98,210 mg n=79。
- Abrilumab 7、21、70 mg于第1天、第2周和第4周皮下给药,之后每4周一次;210 mg仅第1天给药;安慰剂对照。
- 主要终点为第8周时两个最高剂量组的缓解(总Mayo评分≤2分,且无单项子评分>1分)。
主要发现
- 第8周未调整缓解率:安慰剂组4.3%,Abrilumab 70 mg组13.3%,210 mg组12.7%(70 mg和210 mg vs 安慰剂,P<.05)。
- 达到缓解的比值:Abrilumab 70 mg组比值比3.35(90% CI 1.41-7.95;P=.021),210 mg组比值比3.33(90% CI 1.34-8.26;P=.030),均高于安慰剂。
- Abrilumab 70 mg和210 mg组的临床应答率和黏膜愈合率(中心判读)也显著高于安慰剂。
- 基线初始CD4+ T细胞α4β7水平较高是总体结局的预后指标,但不是Abrilumab应答的预测生物标志物。
- 未发生进行性多灶性白质脑病或死亡病例。
关键数值与推荐
- 主要终点缓解定义:总Mayo评分≤2分,且无单项子评分>1分。
- 关键次要终点:第8周临床应答和黏膜愈合(中心判读)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The α4β7 integrin is a validated target in inflammatory bowel disease. This randomized, phase 2b, placebo-controlled, double-blind study evaluated the efficacy and safety of the anti-α4β7 antibody abrilumab in patients with moderate-to-severe ulcerative colitis despite treatment with conventional therapies. METHODS: Patients (total Mayo Score 6-12, recto-sigmoidoscopy score ≥2) with inadequate response or intolerance to conventional therapies were randomized to receive subcutaneous abrilumab (7, 21, or 70 mg) on day 1, weeks 2 and 4, and every 4 weeks; abrilumab 210 mg on day 1; or placebo. The primary end point was remission (total Mayo Score ≤2 points, no individual sub-score >1 point) for the 2 highest dosages at week 8. Key secondary end points were response and mucosal healing (centrally read) at week 8. RESULTS: For 354 patients who received ≥1 dose of investigational product (placebo, n = 116; 7 mg, n = 21; 21 mg, n = 40; 70 mg, n = 98; 210 mg, n = 79), non-adjusted remission rates at week 8 were 4.3%, 13.3%, and 12.7% for the placebo and abrilumab 70-mg and 210-mg groups, respectively (P < .05 for 70 and 210 mg vs placebo); odds of achieving remission were significantly greater with abrilumab 70 mg (odds ratio 3.35; 90% CI 1.41-7.95; P = .021) and 210 mg (odds ratio 3.33; 90% confidence interval 1.34-8.26; P = .030) than with placebo. Response and mucosal healing rates with these dosages also were significantly greater than with placebo. Higher baseline α4β7 levels on naïve CD4+ T cells were a prognostic indicator for overall outcome, but not a predictive biomarker of abrilumab response. There were no cases of progressive multifocal leukoencephalopathy or deaths. CONCLUSIONS: Abrilumab treatment for 8 weeks induced remission, clinical response, and mucosal healing in patients with moderate-to-severe ulcerative colitis. ClinicalTrials.gov, number NCT01694485.
引用
- Sandborn WJ, Cyrille M, Hansen MB, et al. Efficacy and Safety of Abrilumab in a Randomized, Placebo-Controlled Trial for Moderate-to-Severe Ulcerative Colitis. Gastroenterology. 2018. PMID: 30472236. doi:10.1053/j.gastro.2018.11.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。